Tarek Mekhail is an Oncology physician affiliated with AdventHealth Orlando. OpenAlex indexes 258 publications with 22,147 citations (h-index 47); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2501 N Orange Ave
Suite 689
Orlando, FL 328044603
Telephone
407-265-6627Registry record last updated 1 Apr 2013.
Clinical trials
- Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
Sponsor: The Cleveland Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202562 payments$138,570openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202549 payments$101,193openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year202545 payments$47,706openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
41%Opioid Agonist17.7%Oxycodone-Acetaminophen57%Oxycodone Hcl28%Morphine Sulfate Er15%Part D<11 patientsPhenothiazine10.6%Prochlorperazine Maleate100%Part D≥68 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.9%Serotonin-3 Receptor Antagonist13.4%Ondansetron Hcl89%Ondansetron Odt11%Part D<11 patientsCorticosteroid4.4%Prednisone100%Part D≥18 patients+ 2 more classes in this area
Cancer & immunology
18.8%Kinase inhibitor8.5%Tagrisso51%Mekinist20%Alecensa15%Calquence15%Part D<11 patientsThalidomide Analog7.6%Revlimid54%Lenalidomide46%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bridget Koontz, MD
AdventHealth Orlando
Ayman Koteish, MD
AdventHealth Orlando
Chandra Bomma, MD
AdventHealth Orlando
Mohamedtaki Tejani, MD
AdventHealth Orlando
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”